AI tailors cancer cocktails: smart dosing trial launches

NCT ID NCT05381038

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 21 times

Summary

This early-phase study tests whether artificial intelligence can help doctors choose and dose the right combination of cancer drugs for each person with a solid tumor (like breast or gastrointestinal cancer). Researchers will use a patient's own tumor sample in the lab to find the most effective drug mix, then an AI system called CURATE.AI will adjust doses over time to maximize benefit while staying safe. The main goal is to see if this personalized approach is practical and worth testing in a larger trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National University Hospital

    RECRUITING

    Singapore, 119074, Singapore

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.